Sun Pharma net up 2.5%, US revenues down 4%

Sun Pharmaceutical Industries, India’s largest formulation player by market share and a leading exporter to the US markets, posted an 8.93 per cent growth in revenues to %14,478 crore in Q2FY26, while the net profit grew by 2.56 percent year-on-year (Y-0-Y) to €3,118 crore.

- SOHINI DAS

The jump was led by growth in India, emerging markets and the rest of the world. However, US revenues were down 4.1percent.

The results beat Bloomberg analyst estimates who had forecast revenues of %14,244 crore with adjusted net income of %2,881 crore. The stock was down marginally at the end of day’s trade most likely due to the US business overhang.